Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy

References

• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association.
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. [Internet]. 2010 October. Available from: http://psychiatryon line.org/content.aspx?bookid = 28&sectionid = 1667485.
   Google Scholar
• Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. 2008. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343–396.
   PubMed Web of Science ®Google Scholar
• Barnes TRE. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.
   PubMed Web of Science ®Google Scholar
• Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8:67–104.
   PubMed Web of Science ®Google Scholar
• Burman CF, Sonesson C, Guilbaud O. 2009. A recycling framework for the construction of Bonferroni-based multiple tests. Stat Med 28:739–761.
   PubMed Web of Science ®Google Scholar
• Clayton AH, McGarvey EL, Clavet GJ. 1997. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 33:731–745.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Gaynes BN, Warden D, et al. 2010. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry 22:43–55.
   PubMed Web of Science ®Google Scholar
• Dunbar G, Hosford D. 2010. The potential of the nicotinic channel blocker TC-5214 as augmentation treatment in patients with major depression [abstract]. Eur Neuropsychopharmacol 20(Suppl 3):S334.
   Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321–326.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. 1990. EuroQol – a new facility for the measurement of health-related qualilty of life. Health Policy 16:199–208.
   PubMed Web of Science ®Google Scholar
• Guy W. 1976a. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ no ADM 766–338). Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. p 534–537.
   Google Scholar
• Guy W. 1976b. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare. p 218–222.
   Google Scholar
• Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50–55.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. 1996. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 168:17–30.
   Google Scholar
• Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, et al. 2008. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 14:266–277.
   PubMed Web of Science ®Google Scholar
• Mineur YS, Picciotto MR. 2010. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31:580–586.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (National Clinical Practice Guideline 90) [Internet]. 2009 October. Available from: http://www.nice.org.uk/nicemedia/pdf/Depression_Update_FULL_GUIDELINE.pdf
   Google Scholar
• Nemeroff CB. 2007. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8):17–25.
   PubMedGoogle Scholar
• Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP. 2013. Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacol Biochem Behav 108:28–43.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Charles D, Fava M. 2010. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomised, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 11:300–307.
   PubMed Web of Science ®Google Scholar
• Posner K, Oquendo M, Stanley B, Gould M. 2005. Suicidality Classification Project.
   Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 44: 77–87.
   PubMed Web of Science ®Google Scholar
• Rush AJ. 2007. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry 68(Suppl 10):8–10.
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Sheehan DV. 2000. Sheehan Disability Scale. In: Handbook of psychiatric measures. Washington, DC: American Psychiatric Association, pp. 113–115.
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33.
   PubMed Web of Science ®Google Scholar
• Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. 2002. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525–535.
   PubMed Web of Science ®Google Scholar
• Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, et al. 2010. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomised controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71:270–279.
   PubMed Web of Science ®Google Scholar
• Vieta E, Thase ME, Naber D, D'Souza B, Rancans E, Lepola U, et al. 2014. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. European Neuropsychopharmacology 24:564–574.
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. 2013. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 150:384–388.
   PubMed Web of Science ®Google Scholar